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further optimized these compounds to prepare a class of novel pyrazole derivatives by opening the fused-
ring system. Several new compounds exhibited more potent inhibitory activity than the lead compounds
against 5-LOX. In particular, compound 4e not only suppressed lipopolysaccharide-induced inﬂammation
in brain inﬂammatory cells and protected neurons from oxidative toxicity, but also signiﬁcantly decreased
infarct damage in a mouse model of cerebral ischemia. Molecular docking analysis further conﬁrmed the
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Structural optimization and biological evaluation of 1,5-disubstituted pyrazole-3-carboxamines 33in vivo inhibitory activities of these compounds against 5-LOX suggested that these novel chemical
structures have a promising therapeutic potential to treat leukotriene-related disorders.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
5-Lipoxygenase (5-LOX) is the key enzyme that metabolizes
arachidonic acid (AA) into the bioactive leukotrienes (LTs), whichsign of novel 1,5-disubstituted pyr
activity against 5-LOX in rat peri
R2
2NH2
2NH2
2NH2
2NH2
2NH2
2NH2are considered to be potent mediators of inﬂammatory responses1,2.
Accumulated evidence suggested that LTs play important roles in the
development of allergic diseases such as asthma3–5, various inﬂam-
matory disorders such as rheumatoid arthritis and cardiovascularazole-3-carboxamines by fused-ring cracking.
toneal polymorphonuclear leukocytes (PMNLs).
Inhibition at 5 μmol/L (%)a
55.7
65.7
74.9
59.0
90.1
50.7
Table 1 (continued )
Compd. R1 R2 Inhibition at 5 μmol/L (%)a
4g SO2NH2 66.1
4h SO2NH2 39.3
4i SO2NH2 61.9
4j SO2NH2 69.2
4k SO2NH2 74.5
5a SO2CH3 41.9
5b SO2CH3 62.8
5c SO2CH3 35.6
5d SO2CH3 60.2
5e SO2CH3 79.3
5f SO2CH3 70.3
5g SO2CH3 51.7
5i SO2CH3 69.6
5j SO2CH3 57.3
6a F 56.8
6b F 83.7
aValues are means of three determinations and deviation from the mean is o10% of the mean value (Catalog No. 520111, Cayman
Chemicals Inc.).
Yu Zhou et al.34diseases5,6. LTs also contribute to tumorigenesis including of the
prostate, pancreatic cancer and leukemia7,8. Moreover, 5-LOX
expression and its enzymatic activity are increased after focal cerebral
ischemia and 5-LOX plays an important role in the pathogenesis of
cerebral ischemia9. Therefore, pharmacological interference with the
5-LOX pathway to down-regulate the formation of LTs is a
promising therapeutic strategy for LT-related diseases.
In search of pharmacological agents that suppress the biosynthesis
of LTs, different types of small molecular inhibitors of 5-LOX have
been developed in the past two decades, such as redox inhibitors,
iron-chelator agents and non-redox competitive inhibitors10,11. To
date, despite considerable efforts devoted to the development of
efﬁcient and safe drugs that target the 5-LOX pathway, only one 5-
LOX inhibitor, Zileuton (1, Scheme 1), has been approved for asthma
treatment12, although it still exhibits several drawbacks, including
liver toxicity and unfavorable pharmacokinetic proﬁle with a short
half-life3. Therefore, there is an urgent need to develop novel drugs
without the disadvantages of previous 5-LOX inhibitors10. In fact,
considerable efforts have been directed recently toward the identiﬁca-
tion of higher efﬁcacy 5-LOX inhibitors to reduce side effects
through diverse medicinal chemistry approaches12, such as leadidentiﬁcation13, scaffold-hopping14, structure-based drug design15,
dynamic modeling16, and structural optimization17.
In our previous studies we identiﬁed a series of novel indole
derivatives with potent inhibitory activities against 5-LOX by structural
optimization for the hit compound 2, which originated from our in-
house collection18. Among them, compounds 3a and 3b exhibited the
most potent inhibitory proﬁle with IC50 values of less than 1 mmol/L in
the cell-based assay, and thus seem to be the promising lead compounds
for treating LT-related diseases18. Here, we further optimized this class
of compounds in an attempt to improve their druggability by splitting
the indole ring to reconstruct the core scaffold and introducing a 5-LOX
inhibitor pharmacophore (3,5-di-tert-butyl-4-hydroxyphenyl)19–21 to
form substituted pyrazole-3-carboxamine derivatives (Scheme 1). Sev-
eral optimized compounds displayed more potent inhibitory activities
than the lead compounds 3a, 3b and the reference drug 1 against 5-
LOX in peritoneal polymorphonuclear leukocytes (PMNLs), human
whole blood (HWB), and enzymatic assays. Further investigations
indicated that compound 4e not only effectively suppressed LPS-
induced inﬂammation in brain inﬂammatory cells and protected neurons
from oxidative toxicity in vitro, but also signiﬁcantly decreased infarct
volumes in a mouse model of cerebral ischemia.
Scheme 3 The synthetic strategy for the target compounds. Reagent and conditions: (a) diethyl oxalate, NaH, toluene, 45 oC, 2 h; (b) C2H5OH,
reﬂux, 12 h; (c) (i) Na, C2H5OH, diethyl oxalate, 15 h, (ii) HCl, reﬂuxing, 12 h; (d) LiOH, H2O, THF, rt, 12 h; (e) (i) SOCl2, CH2Cl2, reﬂux, 2 h,
(ii) pyridine, CH2Cl2, 25
oC, 12 h.
Scheme 2 Synthetic routes of key intermediates 9 and 12. Reagent and conditions: (a) HNO3, H2O, hexane, 55
oC; (b) Sn/HCl, C2H5OH, reﬂux;
(c) NaNO2, HCl, H2O; (d) SnCl2, HCl.
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2.1. Chemistry
In the current studies, novel pyrazole-scaffold derivatives have
been explored through a fused-ring cracking strategy with our
previous lead compounds to further optimize the structural features
and improve their in vitro and in vivo biological effects. Asdepicted in Scheme 1, compounds (4a–k, 5a–j and 6a–b, Table 1)
were obtained by splitting the indole ring of the lead compounds
(3a and 3b) to reconstruct the pyrazole scaffold and simulta-
neously introduce the 3,5-di-tert-butyl-4-hydroxyphenyl segment.
Firstly, by introducing a 4-aminosulfonylphenyl group onto the 1-
N position of the pyrazole ring, we obtained compounds 4a–k by
introducing different R2 groups with various steric, electron-
donating groups, electron-withdrawing groups and alkyl groups.
Yu Zhou et al.36Then compounds 5a–j were obtained by replacing the 4-
aminosulfonylphenyl group of compounds 4a–j with a p-methyl-
sulfonylphenyl group. Finally, we introduced a ﬂuorine group to
the R1 position to explore the biological inﬂuences against 5-LOX.
As shown in Scheme 2, key intermediate 9 was synthesized by the
nitration of the commercially available 2,6-di-tert-butylphenol (7)
with aqueous HNO3 in hexane to give 2,6-di-tert-butyl-4-nitro-
phenol (8), which was then reduced with Sn/HCl under reﬂux
conditions with a 70%–80% yield. Another key intermediate, 4-
aminosulfonylphenylhydrazine hydrochloride (12), was prepared
according to a similar method reported previously22,23. Commer-
cially available sulfanilamide (10) was converted into its diazo-
nium salt by reaction of the amine with in situ generated nitrous
acid. The diazonium salt 11 was subsequently reduced to
hydrazine 12 with SnCl2 in acidic medium. The synthetic strategy
for the target compounds are shown in Scheme 3. The important
pyrazole intermediates 17a–k were synthesized starting from
commercially available substituted actones, which were ﬁrstly
reacted with diethyl oxalate in the presence of NaH to give β-Figure 1 Compound 4e inhibited LPS-induced inﬂammation in BV2 cells
at 10, 50 and 100 μmol/L signiﬁcantly attenuated NO production in cells t
tested concentrations did not exhibit toxicity to BV2 cells regardless of the
treated with LPS (n ¼ 3).
Table 2 Determination of IC50 values of the selected
compounds in PMNL, HWB and in the enzymatic assay.
Compd. IC50/μmol/L
PMNL HWB Enzymatic assaya
4c 0.45 4.87 0.13670.015
4e 0.69 1.08 0.13370.014
4g 0.75 2.11 0.16570.017
4j 1.07 33.9 b
4k 0.90 5.83 0.15970.016
5e 0.64 0.94 0.16970.016
5f 0.81 4.65 0.27370.021
5i 0.80 1.13 0.12770.029
6b 0.82 10.2 0.32770.022
Zileuton 1.19 4.83 0.206
HWB, human whole blood; PMNL, rat peritoneal polymorpho-
nuclear leukocytes.
aEach concentration was tested in triplicate. The IC50 was
calculated with the sigmoidal dose-response (variable slope) ﬁtting
equation in GraphPad Prism.
bNot determined.diketone intermediates 14a–k, followed by reacting with 4-
aminosulfonylphenylhydrazine hydrochloride (12) in ethanol
under reﬂux condition for 12 h. Compounds 17a–k were also
produced by a one-pot two-step process. Initially, Na was treated
with absolute ethanol at room temperature until it was completely
dissolved, substituted acetones (13a–k) and diethyl oxalate were
then added, and the resulting mixture was reﬂuxed for 15 h. After
the reaction mixture was cooled to ambient temperature, equiva-
lent HCl solution and the corresponding hydrazines were added to
the crude reaction mixture, which was further heated to reﬂux for
another 12 h to give the desired compounds. Subsequently,
hydrolysis of compounds 17a–k gave the corresponding acids
(20a–k), which then underwent a simple condensation reaction
with the key intermediate 9 to give the target 1,5-disubstituted
pyrazole-3-carboxamines 4a–k. Other desired compounds, 5a–j
and 6a–b were also prepared using a similar process to 4a–k.
2.2. Biological evaluations
All derivatives (4a–k, 5a–j, and 6a–b, Table 1) were evaluated
using a cell-based assay for their inhibition of 5-LOX product
synthesis at 5 μmol/L concentration in rat peritoneal polymorpho-
nuclear leukocytes (PMNL) using zileuton, a potent 5-LOX
inhibitor, as the reference drug18,24. Nine compounds were
selected to explore their concentration-response relationship in
PMNLs, human whole blood (HWB) and 5-LOX enzymatic level
assays. Compound 4e was further evaluated for its suppressive
effects on lipopolysaccharide (LPS)-induced inﬂammation in brain
inﬂammatory cells and protective effects against oxidative toxicity. (A) LPS-induced production of NO compared to saline: compound 4e
reated with LPS; (B) cell viability in MTT assay: compound 4e at the
presence or absence of LPS. **Po0.01 compared with the cells only
Figure 2 Compound 4e protected HT22 neuronal cells against
glutamate oxidative toxicity at 1, 10, 50 and 100 μmol/L. **Po0.01
compared with the glutamate-treated cells (n ¼ 3). Glu: glutamate.
Figure 3 Compound 4e reduced infarct volumes at 24 h after reperfusion in the mouse MCAO model. Compared to vehicle treatment, post-
ischemic administration of 4e signiﬁcantly decreased cortical, striatal and hemispheric infarct volumes. (A) representative images of
5-tripheyltetrazolium chloride (TTC) staining (white: infracted area; red: viable tissue); (B) the bar graph of TTC histology. **Po0.01 and *
Po0.05 compared with vehicle-treated mice (n ¼ 7).
Figure 4 Putative binding mode of 4e in the 5-LOX structure, where
the catalytic pocket of 5-LOX is depicted as a gray surface and the key
interacting amino acids are shown. The image was generated using
PyMOL, version 1.3.
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compound 4e for reducing brain infarction using a well-established
mouse model of experimental stroke.2.2.1. Structure–activity relationship of pyrazole-3-carboxamine
derivatives
For the preliminary assay, the percent inhibition of 5-LOX
formation of all compounds at 5 μmol/L in rat PMNLs was
measured. The results are summarized in Table 1. The details of
the bioassay procedures are described in the experimental section.
As shown in Table 1, all compounds demonstrated good inhibitory
activity against 5-LOX in rat PMNLs. The inhibition rates of 14
compounds were more than 60% at 5 μmol/L. Further studies
showed that introducing substituents (electron-donating or electron-
withdrawing groups), except the ﬂuoro group, into the phenyl ringof R2 group increased the inhibitory activities against 5-LOX
product synthesis when R1 was replaced by an aminosulfonyl
group (4a–i). The introduction of a benzo[d] [1, 3] dioxol-5-yl
group afforded the most potent inhibitory effects toward 5-LOX
product synthesis, with 90.1% inhibition at 5 μmol/L. Additionally,
introducing an alkyl group (cyclohexyl, 4j) and an aryl heterocyclic
group (5-bromothiophen-2-yl, 4k) also improved inhibition potency
against 5-LOX compared to the non-substituted compound 4a (the
inhibition rate: 69.2% vs. 74.5%, respectively). In the second round
of structural optimization, we replaced the 4-aminosulfonyl moiety
on the phenyl ring of compounds 4a–k with a 4-methylsulfonyl
moiety to give compounds 5a–j. Biological evaluation showed that
the inhibition potency of most substituted derivatives was superior
to that of non-substituted compound 5a. The compound substituted
by a benzo-fused ﬁve-member heterocycle (5e) exhibited the most
potent inhibitory activity against 5-LOX product synthesis in rat
PMNLs with 79.3% inhibition at 5 μmol/L. Finally, we further
explored the effects of a ﬂuoro substituent in the R1 position on
inhibitory potency of 5-LOX. The biological results indicated that
introducing ﬂuoro substituent to the pyrazole scaffold (6a and 6b)
also improved the inhibitory activity.
To further characterize the potency of the compounds, nine
were selected for further investigation in concentration-response
studies. The results are summarized in Table 2. All selected
compounds showed prominent inhibitory activities, with IC50
values ranging from 0.45 μmol/L to 1.07 μmol/L. Compounds
4c, 4e, 4g, 4k, 5e, 5f, 5i and 6b exhibited better inhibitory proﬁles
(with IC50 values less than 1 μmol/L) compared with the reference
drug zileuton. Meanwhile, the efﬁcacies for inhibition of 5-LOX
were also determined in the human whole blood (HWB) model. As
shown in Table 2, the nine selected compounds showed good
inhibitory activities against 5-LOX product synthesis. Compounds
with benzo-fused ﬁve-member heterocycles (4e and 5e) exhibited
the most potent inhibitory activity against 5-LOX, and these
results were consistent with the results obtained from the
PMNL model.
To assess the inhibitory potency directly against 5-LOX, we
used a cell-free assay to examine the inhibitory effects of eight
compounds on the enzymatic activity of human 5-LOX. As shown
in Table 2, most of the compounds exhibited much higher 5-LOX
Figure 5 A schematic depiction of detailed interaction of 4e within the active site of 5-LOX, where distinctive colors and shapes are used to
describe the different types of interactions. The diagram was generated using Maestro 9.1.
Yu Zhou et al.38inhibition than the reference drug zileuton. Compounds 4e, 4g, 5e
and 5i not only displayed excellent inhibitory activities against 5-
LOX in rat PMNL and HWB models, but also effectively inhibited
the enzymatic activity of human 5-LOX in the cell-free assay. It
appears that introducing benzo-fused ﬁve-member heterocyle (4e
and 5e) is favorable for the inhibitory activity against 5-LOX.
These results indicated that these compounds were highly effective
5-LOX inhibitors, which may possess potential for the treatment of
LT-related diseases. Therefore, compound 4e was selected to
further evaluate its protective effects against ischemic insults using
in vitro and in vivo approaches.
2.2.2. Compound 4e suppresses LPS-induced inﬂammation in vitro
Nitric oxide (NO) served as a proinﬂammatory marker and its
production was induced upon LPS stimulation in the BV2 cells.
Thus, we used a mouse microglia cell line BV2 to evaluate the
suppressive effects of compound 4e on LPS-induced inﬂammation.
NO production of microglia was generally evaluated by measuring
nitrite released into the media. As shown in Fig. 1A, LPS at
200 ng/mL signiﬁcantly induced the production of NO in BV2
cells, as indicated by signiﬁcantly higher levels of nitrite in BV2
cells exposed to LPS vs. those exposed to saline. LPS-induced
generation of NO was remarkably attenuated by the addition of 4e
at 10, 50 or 100 μmol/L, while at the tested concentrations 4e did
not reduce the viabilities of BV2 cells regardless of the presence or
absence of LPS (MTT results, Fig. 1B). The results suggest that 4e
was effective in suppressing LPS-induced inﬂammation in brain
inﬂammatory cells.
2.2.3. Neuroprotective effects of 4e against glutamate-induced
oxidative toxicity
Glutamate toxicity is a critical contributor to the pathogenesis of
multiple neurological diseases, including ischemic stroke. In HT22
cells which lack functional glutamate receptors, glutamate-inducedneurotoxicity has been exclusively attributed to oxidative stress25.
Therefore, we assessed the neuroprotective effects of compound 4e
against glutamate-induced oxidative toxicity in HT22 cells with
MTT assay. The viability of HT22 was decreased signiﬁcantly at
24 h after glutamate exposure. The novel compound 4e at
concentrations between 1–100 μmol/L remarkably reduced
glutamate-induced HT22 cell death (Fig. 2), suggesting that
compound 4e was effective in protecting neurons from oxidative
toxicity.
2.2.4. Protective effects against ischemic damage in vivo
As a major enzyme responsible for leukotriene biosynthesis and
with an induced expression pattern following cerebral ischemia, 5-
LOX plays an important role in the pathogenesis of cerebral
ischemia1. The above in vitro results demonstrated that compound
4e not only effectively suppressed LPS-induced inﬂammation in
brain inﬂammatory cells, but also directly protected neurons from
oxidative toxicity. Here, we further investigated the protective
effects of compound 4e against infarct damage in the in vivo
mouse middle cerebral artery occlusion (MCAO) model. As
shown in Fig. 3, compared with vehicle treatment, post-ischemic
intraperitoneal (IP) administration of compound 4e signiﬁcantly
decreased cortical, striatal and hemispheric infarct volumes after
24 h in the MCAO model.
2.2.5. Molecular modeling
To better rationalize the structure-activity relationships (SARs) for
the pyrazole derivatives, molecular docking studies were per-
formed for compound 4e. Here the computations aimed to
elucidate the structural requisites responsible for binding at the
5-LOX active sites. As shown in Fig. 4, compound 4e ﬁts into the
binding site with the 3,5-di-tert-butyl-4-hydroxyphenyl head
approaching the Fe2þ ion, and the pyrazole ring inserting into a
narrow groove formed by Gln363 and Ala603. The central
Structural optimization and biological evaluation of 1,5-disubstituted pyrazole-3-carboxamines 39carboxamide group bridging between these two moieties forms a
hydrogen bond via its oxygen atom to Gln363. This binding
pattern was followed by all the pyrazole derivatives examined
here, which explains the overall effectiveness of this series of
compounds against 5-LOX. In addition to this common binding
feature, key interactions were established by the reference com-
pound within the active site. Speciﬁcally, the 1,3-benzodioxol ring
neatly binds into a sterically restricted hydrophobic cavity and is
involved in a π–π stacking with Phe359. A detailed schematic
depiction of the interaction of 4e within the active site of 5-LOX is
shown in Fig. 5, from which we observed that the hydrophobic
contacts involve Phe359, Ala561, ILe564, Leu601, Ala603 and
Val604. A less favorable occupation of the cavity formed by these
residues could contribute signiﬁcantly to the potency. As shown in
Table 1, decreasing the size of R2 led to a similar activity order of
compounds 4e44c44b44a, while more sterically hindering
groups than the 1,3-benzodioxol ring (i.e., compounds 4d, 4f
and 4g) also exhibited reduced activities. Furthermore, the p-
sulfonamide-phenyl branch is exposed to solvent interactions and
located adjacent to a polar region formed by Gln303, Thr570,
His360 and His600. This group establishes an extra key hydrogen
bond via its amino group with the backbone carbonyl oxygen of
Pro569, which explains why replacement of the sulfonamide
substituent with a methylsulfonyl group (compound 5e) resulted
in a loss of the inhibitory activity against 5-LOX. Taken together,
the consistency between the results of our investigations into the
binding mode from theoretical results and the experimental data
further support the rationality of our structure optimization from
the lead compound, which will pave the way for the discovery of
more effective inhibitors of 5-LOX.3. Conclusions
A new class of pyrazole derivatives was designed and synthe-
sized by structural optimization of a lead compound, which
originated from an in-house compound collection, and were
evaluated as 5-LOX inhibitors in PMNLs, HWB and cell-free
enzymatic assays. These pyrazole derivatives exhibited good to
excellent inhibitory activities against 5-LOX in the PMNLs
assay. Nine compounds were selected for concentration–
response studies and displayed prominent inhibitory activities.
Moreover, the nine compounds also displayed excellent biolo-
gical activities in the HWB assay. Among of them, compounds
with a benzo-fused heterocycle (4e and 5e) exhibited the most
potent inhibitory activities against 5-LOX. In the cell-free
assay, several exhibited much higher 5-LOX inhibitory potency
than the reference drug zileuton. In view of the excellent in vitro 5-
LOX inhibitory potency, compound 4e was evaluated for its ability
to protect against ischemic insults. The results suggested that 4e not
only effectively suppressed LPS-induced inﬂammation in brain
inﬂammatory cells and protected neurons from oxidative toxicity,
but also signiﬁcantly decreased cortical, striatal and hemispheric
infarct volumes after 24 h in the mouse MCAO model. Our binding
model also demonstrated the consistency of our results between the
analysis of the binding model from theoretical study and the
experimental data, which further supported the rationale of our
structural optimization. In summary, on the basis of the excellent
inhibitory activities against 5-LOX in vitro and in vivo, these novel
chemical structures have a promising therapeutic potential for LTs-
related disorders.4. Experimental section
4.1. Chemistry
The reagents (chemicals) were purchased from Shanghai
Chemical Reagent Company, Lancaster Company, and Acros
Company, and used without further puriﬁcation. The analytical
thin-layer chromatography (TLC) was HSGF 254 (0.15–0.2 mm
thickness, Yantai Huiyou Company, China). Yields were not
optimized. Melting points (m.p.) were measured in capillary tube
on a SGW X-4 melting point apparatus without correction.
Nuclear magnetic resonance (NMR) spectra were performed on
a Brucker AMX-400 NMR (IS as TMS). Chemical shifts were
reported in parts per million (ppm, δ) downﬁeld from tetramethyl-
silane. Proton coupling patterns were described as singlet (s),
doublet (d), triplet (t), quartet (q), multiplet (m), and broad (br).
Low- and high-resolution mass spectra (LRMS and HRMS) were
given with electric (EI) produced by Finnigan MAT-95 mass
spectrometer.4.1.1. General procedure for the synthesis of 3,5-di-tert-butyl-4-
hydroxyaniline hydrochloride (9)
2,6-Di-tert-butyl-4-nitrophenol (8) was prepared by the previously
reported procedure26. 2,6-Di-tert-butylphenol (10 g) was dissolved
in 40 mL of hexane with heating to 50 1C. Aqueous nitric acid
solution (30%, 17 mL, w/w) was added dropwise to the hexane
solution over 30 min. The reaction temperature was maintained
between 50 1C and 55 1C overnight. The yellow precipitate was
ﬁltered and washed three times with hexane (10 mL 3) followed
by water (10 mL). The resulting yellow solid was dried under
vacuum. Yield: 95%; m.p. 152–155 1C26 (m.p. 155–156 1C).
1H NMR (CDCl3) δ 8.14 (s, 2 H), 5.94 (s, 1 H), 1.49 (s, 18 H).
The 1H NMR spectrum is consistent with that of the reference
reported26.
Compound 8 (1.0 mmol) was dissolved in 20 mL of ethanol and
2.0 mmol of Sn and 4 mL of concentrated hydrochloric acid were
added into the ethanol solution. The resulting reaction mixture was
heated to reﬂux for 2 h27. After ﬁltering the mixture, most solvent
was evaporated under reduced pressure and the residue was cooled
in refrigerator. The white precipitate, 3,5-di-tert-butyl-4-hydro-
xyaniline hydrochloride (6), was obtained by ﬁltering, washing
three times with cooled-ethanol, and dried in vacuum. Yield: 90%;
m.p. 199–201 1C. 1H NMR (CDCl3) δ 6.61 (s, 2 H), 1.43 (s,
18 H); EI–MS m/z 221 (Mþ).4.1.2. General procedure for the synthesis of (4-aminosulfonyl)
phenylhydrazine hydrochloride (12)
The key intermediate (4-aminosulfonyl)phenylhydrazine hydro-
chloride (12) could prepared according to the reported method2,3.
To a solution of sulfanilamide (6.9 g, 40.0 mmol, 1.0 eq) in conc.
HCl (30 mL) was added a solution of sodium nitrate (3.1 g,
44.0 mmol, 1.1 eq) in 12.0 mL of water over 15 min in an ice-
water bath. The resulting mixture was rapidly added to a cooled
(0 1C) solution of tin (II) chloride dihydrate (27.1 g, 120.0 mmol,
3.0 eq) in conc. HCl (30 mL), followed by a stirring for 1 h, then
overnight at ambient temperature. The precipitate was collected by
ﬁltration and successively washed with cool water and Et2O to
give the pure compound, which was used directly without further
puriﬁcation.
Yu Zhou et al.404.1.3. General procedures for the synthesis of intermediates
17a–k, 18a–j and 19a–b as described for ethyl 1-(4-aminosulfon-
ylphenyl)-5-phenyl-1H-pyrazole-3-carboxylate (17a)
To a stirred solution of NaH (2 mmol) in 10 mL of toluene was
added acetophenone (1 mmol) in 10 mL of toluene. The mixture
was heated to 45–50 1C, followed by the addition of diethyl
oxalate (2 mmol) in 5 mL of toluene, and the resulting mixture was
stirred at reﬂuxing for 2 h. The solvent was removed under
reduced pressure and the residue was extracted with EtOAc
(20 mL 3), the organic layer was washed by 20 mL of aqueous
sodium bicarbonate solution and brine, dried with anhydrous
MgSO4, and ﬁltered and concentrated under reduced pressure to
obtain the crude product, which was further puriﬁed by ﬂash
chromatography on silica gel (hexane/EtOAc¼4:1) to afford the
desired products. The resulting intermediate 14a (1 mmol) was
added to a solution of 1-(4-(aminosulfonyl)phenyl)hydrazine (12,
1 mmol) in 20 mL of ethanol, and heated to reﬂux overnight. After
cooling the reaction mixture to ambient temperature, the solvent
was removed under reduced pressure. Water (20 mL) was added to
the residue, extracted with EtOAc (20 mL 3), the resulting
organic layer was washed by brine, dried with anhydrous
MgSO4, ﬁltered and concentrated under reduced pressure to obtain
the crude product, which was further puriﬁed by ﬂash chromato-
graphy on silica gel (hexane/EtOAc¼2:1) to afford the target
products 14a as a yellow solid.
Alternatively, a one-pot, two-step process was also carried out
to synthesize the target 14a. To a solution of sodium ethoxide,
prepared by dissolving Na (1 mmol) in 20 mL of anhydrous
ethanol, was added acetophenone (1 mmol). After about 30 min,
diethyl oxalate (1 mmol) was added. The resulting mixture was
heated to reﬂux for 15 h and then cooled to the room temperature.
During this time the sodium salt of the intermediate β-diketonate
condensation product precipitated as a thick yellow paste. HCl
(1.2 mmol) and the corresponding hydrazines (1 mmol) were
added and the mixture was stirred for another 12 h. Most of
solvent was removed under reduced pressure and the residue was
cooled to precipitate a thick yellow solid, which was ﬁltered off
and dried in vacuum to obtain the title compound 14a. m.p. 182–
186 1C. 1H NMR (CDCl3) δ 1.43 (t, 3H), 4.46 (q, 2H), 5.11 (br,
2H), 7.04 (s, 1H), 7.20 (m, 2 H), 7.36 (m, 3H), 7.46 (d, 2H), 7.87
(d, 2H); LRMS (EI) m/z 371 (Mþ).4.1.4. General procedure for the preparations of compounds
4a–k, 5a–j, 6a–b are described as that for N-(3,5-di-tert-butyl-4-
hydroxyphenyl)-1-(4-aminosulfonyl-phenyl)-5-phenyl-1H-pyrazole-
3-carboxamide (4a)
A solution of ethyl 1-(4-aminosulfonylphenyl)-5-phenyl-1H-pyr-
azole-3-carboxylate (17a, 1 mmol) and potassium hydroxide
(2 mmol) in water (30 mL) was heated to reﬂux for 0.5 h, and
then allowed to cool to room temperature. After acidiﬁcation with
aqueous hydrochloric acid (2 mol/L), the mixture was extracted
with EtOAc (20 mL 3) and the organic layer was washed by
brine, dried with anhydrous MgSO4, ﬁltered and concentrated
under reduced pressure to afford the crude product 20a as a yellow
solid, which was directly used without further puriﬁcation.
To a solution of the intermediate 17a (1 mmol) in 15 mL of
CH2Cl2 was added 2 mL of SOCl2 and the resulting mixture was
heated to reﬂux for 3 h. After evaporation of the solvent under
reduced pressure, 15 mL of CH2Cl2 was added, followed by the
addition of 3,5-di-tert-butyl-4-hydroxyaniline hydrochloride
(1 mmol) and 5 mL of pyridine and the resulting mixture wasstirred overnight at room temperature. The solvent was evaporated
under reduced pressure and the residue was dissolved in 20 mL of
H2O, extracted by CH2Cl2 (20 mL 3), the organic layer was
washed by aqueous hydrochloric acid, saturated NaHCO3, and
brine, and dried with anhydrous MgSO4. The solvent was
evaporated under reduced pressure and the residue was puriﬁed
by column chromatography to obtain the target compounds 4a as a
pale yellow solid. m.p. 233–235 1C; 1H NMR (500 MHz,
DMSO-d6) δ 9.91 (s, 1H), 7.88 (d, J¼8.6Hz, 2H), 7.64 (s, 2H),
7.59 (d, J¼8.6 Hz, 2H), 7.50 (s, 2H), 7.45–7.41 (m, 3H), 7.36–
7.31 (m, 2H), 7.14 (s, 1H), 6.81 (s, 1H), 1.40 (s, 18H); 13C NMR
(125 MHz, DMSO-d6) δ 159.53, 150.57, 148.63, 145.07, 144.04,
142.06, 140.14, 131.60, 129.53, 129.34, 129.23, 127.15, 126.34,
117.96, 109.08, 35.24, 30.87; LRMS (EI) m/z 546 (Mþ); HRMS
(EI) m/z Calcd. for C30H34N4O4S (M
þ) 546.2301, Found:
546.2312.4.1.5. N-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-(4-aminosulfonylphe-
nyl)-5-p-tolyl-1H-pyrazole-3-carboxamide (4b)
This compound was prepared from 40-methylacetophenone by
using a procedure similar to that described for the preparation of
4a. A pale yellow solid, mp 184–187 1C; 1H NMR (500 MHz,
DMSO-d6) δ 9.89 (s, 1H), 7.89 (d, J¼8.5 Hz, 2 H), 7.67–7.56 (m,
4H), 7.50 (s, 2H), 7.28–7.19 (m, 4H), 7.09 (s, 1H), 6.81 (d,
J¼2.9 Hz, 1H), 2.33 (s, 3H), 1.40 (s, 18H); 13C NMR (125 MHz,
DMSO-d6) δ 159.56, 150.55, 148.59, 145.13, 143.98, 142.14,
140.13, 139.15, 131.61, 129.91, 129.10, 127.15, 126.64, 126.32,
117.94, 108.79, 35.24, 30.87, 21.29; LRMS (EI) m/z 560 (Mþ);
HRMS (EI) m/z Calcd. C31H36N4O4S (M
þ) 560.2457, Found
560.2441.4.1.6. N-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-(4-aminosulfonylphe-
nyl)-5-p-meth- oxyphenyl-1H-pyrazole-3-carboxamide (4c)
This compound was prepared from 40-methoxyacetophenone by
using a procedure similar to that described for the preparation of
4a. A white solid, mp 219–221 1C; 1H NMR (500 MHz,
DMSO-d6) δ 9.87 (s, 1H), 7.89 (d, J¼8.6 Hz, 2H), 7.63 (s, 2H),
7.59 (d, J¼8.6 Hz, 2H), 7.50 (s, 2H), 7.26 (d, J¼8.7 Hz, 2H),
7.06 (s, 1 H), 6.99 (d, J¼8.8 Hz, 2H), 6.81 (s, 1H), 3.78 (s, 3H),
1.39 (s, 18H); 13C NMR (125 MHz, DMSO-d6) δ 160.18, 159.61,
150.55, 148.53, 144.98, 143.91, 142.20, 140.13, 131.62, 130.64,
127.15, 126.28, 117.94, 114.80, 108.56, 55.74, 35.24, 30.87;
LRMS (EI) m/z 576 (Mþ); HRMS (EI) m/z Calcd. C31H36N4O5S
(Mþ) 576.2406, Found 576.2410.4.1.7. N-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-(4-aminosulfonylphe-
nyl)-5-p-iso-butylphenyl-1H-pyrazole-3-carboxamide (4d)
This compound was prepared from 40-isobutylacetophenone by
using a procedure similar to that described for the preparation of
4a. A yellow solid, mp 155–158 1C; 1H NMR (500 MHz,
DMSO-d6) δ 9.89 (s, 1 H), 7.90–7.86 (m, 2H), 7.64 (s, 2 H),
7.61–7.57 (m, 2H), 7.51 (s, 2 H), 7.29–7.17 (m, 4H), 7.12 (d,
J¼9.6 Hz, 1H), 6.81 (s, 1H), 2.54–2.45 (m, 3H), 1.40 (s, 18H),
0.87 (d, J¼6.6 Hz, 6H); 13C NMR (125 MHz, DMSO-d6) δ
159.57, 150.56, 148.61, 145.20, 143.95, 142.78, 142.16, 140.13,
131.61, 129.88, 128.98, 127.11, 126.95, 126.21, 117.94, 108.85,
44.67, 35.24, 30.87, 29.93, 22.69; LRMS (EI) m/z 602 (Mþ);
HRMS (EI) m/z Calcd. C34H42N4O4S (M
þ) 602.2927, Found
602.2932.
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5-yl)-1-(4-amino-sulfonylphenyl)-1H-pyrazole-3-carboxamide (4e)
This compound was prepared from 3,4-methylenedioxyacetophe-
none by using a procedure similar to that described for the
preparation of 4a. A white solid, mp 180–183 oC; 1H NMR
(500 MHz, DMSO-d6 δ 9.88 (s, 1H), 7.90 (d, J¼8.6 Hz, 2H),
7.68–7.59 (m, 4H), 7.51 (s, 2H), 7.06 (s, 1H), 6.96 (d, J¼8.0 Hz,
1H), 6.92 (s, 1H), 6.84–6.75 (m, 2H), 6.08 (s, 2H), 1.40 (s, 18H);
13C NMR (125 MHz, DMSO-d6) δ 159.56, 150.55, 148.47,
148.39, 147.97, 144.73, 143.92, 142.08, 140.12, 131.52, 127.18,
126.25, 123.53, 123.11, 117.95, 109.54, 109.15, 108.90, 102.04,
35.23, 30.86; LRMS (EI) m/z 590 (Mþ); HRMS (EI) m/z Calcd.
C31H34N4O6S (M
þ) 590.2199, Found 590.2207.4.1.9. N-(3,5-di-tert-butyl-4-hydroxyphenyl)-5-(2,3-dihydrobenzo [1,
4] dioxin-7-yl)-1-(4-aminosulfonylphenyl)-1H-pyrazole-3-carboxamide
(4f)
This compound was prepared from 1,4-benzodioxan-6-yl methyl
ketone by using a procedure similar to that described for the
preparation of 4a. A white solid, mp 276–278 oC; 1H NMR
(500 MHz, DMSO-d6) δ 9.88 (s, 1H), 7.90 (d, J¼8.5 Hz, 2H),
7.65–7.59 (m, 4H), 7.52 (s, 2H), 7.05 (s, 1 H), 6.92–6.85 (m, 2H),
6.82 (s, 1H), 6.72 (dd, J¼8.3, 1.9 Hz, 1H), 4.26 (dd, J¼9.8,
4.6 Hz, 4H), 1.39 (s, 18H); 13C NMR (125 MHz, DMSO-d6) δ
159.57, 150.54, 148.49, 144.64, 144.60, 143.97, 143.85, 142.17,
140.12, 131.59, 127.14, 126.31, 122.44, 122.32, 117.96, 117.94,
117.87, 108.71, 64.65, 64.51, 35.23, 30.86; LRMS (EI) m/z 604
(Mþ); HRMS (EI) m/z Calcd C32H36N4O6S (M
þ) 604.2356,
Found 604.2373.4.1.10. N-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-(4-aminosulfony-
lphenyl)-5-naphth-2-yl-1H-pyrazole-3-carboxamide (4g)
This compound was prepared from 20-acetonaphthone by using a
procedure similar to that described for the preparation of 4a. A
yellow solid, mp 176–177 oC; 1H NMR (500 MHz, DMSO-d6) δ
9.95 (s, 1H), 8.05 (s, 1H), 7.99–7.85 (m, 5H), 7.69–7.56 (m, 6H),
7.49 (s, 2H), 7.32 (dd, J¼8.5, 1.5 Hz, 1H), 7.26 (s, 1H), 6.82 (s,
1H), 1.41 (s, 18H); 13C NMR (125 MHz, DMSO-d6) δ 159.54,
150.55, 148.73, 145.05, 144.01, 142.10, 140.16, 133.12, 133.08,
131.62, 128.79, 128.74, 128.73, 128.16, 127.67, 127.40, 127.21,
126.96, 126.42, 126.23, 117.97, 109.47, 35.25, 30.88; LRMS (EI)
m/z 596 (Mþ); HRMS (EI) m/z Calcd. C34H36N4O4S (M
þ)
596.2457, Found 596.2467.4.1.11. N-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-(4-aminosulfony-
lphenyl)-5-p-ﬂuorophenyl-1H-pyrazole-3-carboxamide (4h)
This compound was prepared from 40-ﬂuoroacetophenone by
using a procedure similar to that described for the preparation of
4a. A pale yellow solid, mp 234–236 oC; 1H NMR (500 MHz,
DMSO-d6) δ 9.91 (s, 1H), 7.89 (d, J¼8.6 Hz, 2H), 7.63 (s, 2H),
7.59 (d, J¼8.6 Hz, 2H), 7.50 (s, 2H), 7.42–7.36 (m, 2H), 7.29 (t,
J¼8.9 Hz, 2H), 7.14 (s, 1H), 6.81 (s, 1H), 1.40 (s, 18H); 13C
NMR (125 MHz, DMSO-d6) δ 162.82 (d, J¼247.0 Hz), 159.49,
150.57, 148.59, 144.06, 141.90, 140.13, 131.62 (d, J¼8.9 Hz),
127.19, 126.35, 126.06, 126.03, 117.96, 116.40 (d, J¼21.8 Hz),
109.20, 35.12, 30.87; LRMS (EI) m/z 564 (Mþ); HRMS (EI) m/z
Calcd. C30H33FN4O4S (M
þ) 564.2207, Found 564.2203.4.1.12. N-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-(4-aminosulfony-
lphenyl)-5-p-triﬂuoromethylphenyl-1H-pyrazole-3-carboxamide (4i)
This compound was prepared from 40-triﬂuoroacetophenone by
using a procedure similar to that described for the preparation of
4a. A white solid, mp 186–189 oC; 1H NMR (500 MHz,
DMSO-d6) δ 9.93 (s, 1H), 8.03 (d, J¼8.7 Hz, 2H), 7.67 (d,
J¼8.6 Hz, 2H), 7.64 (s, 2H), 7.44–7.37 (m, 2H), 7.29 (t, J¼8.8
Hz, 2H), 7.16 (s, 1H), 6.82 (s, 1H), 3.28 (s, 2H), 1.40 (s, 18H);
13C NMR (125 MHz, DMSO-d6) δ 163.84, 161.88, 159.43,
150.59, 148.81, 144.19, 143.33, 140.59, 140.14, 131.66 (d,
J¼8.6 Hz), 131.56, 128.66, 126.49, 125.95, 117.94, 116.45 (d,
J¼21.8 Hz), 109.44, 35.23, 30.86; LRMS (EI) m/z 614 (Mþ);
HRMS (EI) m/z Calcd. C31H33F3N4O4S (M
þ) 614.2175, Found
614.2180.4.1.13. N-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-(4-aminosulfony-
lphenyl)-5-cyclo-hexyl-1H-pyrazole-3-carboxamide (4j)
This compound was prepared from cyclohexyl methyl ketone by
using a procedure similar to that described for the preparation of
4a. A white solid, mp 273–275 oC; 1H NMR (500 MHz,
DMSO-d6) δ 9.74 (s, 1H), 8.02 (d, J¼8.5 Hz, 2H), 7.82 (d,
J¼8.5 Hz, 2H), 7.57 (d, J¼18.2 Hz, 4H), 6.79 (d, J¼14.1 Hz,
2H), 2.75 (t, J¼11.7 Hz, 1 H), 1.84 (d, J¼12.4 Hz, 2H), 1.71 (s,
2H), 1.64 (s, 1H), 1.38 (s, 20H), 1.22 (s, 3H); 13C NMR
(125 MHz, DMSO-d6) δ 159.86, 151.51, 150.46, 148.15, 144.46,
142.02, 140.08, 131.63, 127.41, 126.68, 117.94, 105.08, 35.22,
35.04, 33.06, 30.86, 26.12, 25.74; LRMS (EI) m/z 552 (Mþ);
HRMS (EI) m/z Calcd. C30H40N4O4S (M
þ) 552.2770, Found
552.2758.4.1.14. N-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-(4-aminosulfony-
lphenyl)-5-(5-bromothiophen-2-yl)-1H-pyrazole-3-carboxamide (4k)
This compound was prepared from 2-Acetyl-5-bromothiophene by
using a procedure similar to that described for the preparation of
4a. A white solid, mp 224–225 oC; 1H NMR (500 MHz,
DMSO-d6) δ 9.93 (s, 1H), 7.98 (d, J¼8.6 Hz, 2H), 7.76 (d,
J¼8.6 Hz, 2H), 7.62 (s, 2H), 7.57 (s, 2H), 7.27 (d, J¼3.9 Hz,
1H), 7.26 (s, 1H), 7.05 (d, J¼3.9 Hz, 1H), 6.81 (s, 1H), 1.39 (s,
18H); 13C NMR (125 MHz, DMSO-d6) δ 159.18, 150.59, 148.58,
145.18, 141.38, 140.11, 137.93, 131.67, 131.52, 131.27, 130.16,
127.52, 127.34, 117.99, 114.30, 109.02, 35.23, 30.86; LRMS (EI)
m/z 630 (Mþ); HRMS (EI) m/z Calcd. C28H31BrN4O4S2 (M
þ)
630.0970, Found 630.0982.4.1.15. N-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-(4-methylsulfonyl-
phenyl)-5-phenyl-1H-pyrazole-3-carboxamide (5a)
This compound was prepared from acetophenone by using a
procedure similar to that described for the preparation of 4a. A
yellow solid, mp 165–167 oC; 1H NMR (500 MHz, DMSO-d6) δ
9.93 (s, 1H), 8.02 (d, J¼8.7 Hz, 2H), 7.67 (d, J¼8.7 Hz, 2H),
7.64 (s, 2 H), 7.47–7.41 (m, 3H), 7.38–7.33 (m, 2H), 7.15 (s, 1H),
6.82 (s, 1H), 3.28 (s, 3H), 1.40 (s, 18H); 13C NMR (125 MHz,
DMSO-d6) δ 159.47, 150.58, 148.85, 145.17, 143.48, 140.57,
140.14, 131.58, 129.63, 129.42, 129.39, 129.26, 128.61, 126.46,
117.94, 109.33, 43.70, 35.12, 30.86; LRMS (EI) m/z 545 (Mþ);
HRMS (EI) m/z Calcd. C31H35N3O4S (M
þ) 545.2348, Found
545.2350.
Yu Zhou et al.424.1.16. N-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-(4-methylsulfony-
lphenyl)-5-p-tolyl-1H-pyrazole-3-carboxamide (5b)
This compound was prepared from 40-methylacetophenone by
using a procedure similar to that described for the preparation of
4a. A yellow solid, mp 205–207 oC; 1H NMR (500 MHz,
DMSO-d6) δ 9.91 (s, 1H), 8.02 (d, J¼8.6 Hz, 2H), 7.67 (d,
J¼8.6 Hz, 2H), 7.64 (s, 2H), 7.26–7.20 (m, 4H), 7.10 (s, 1H),
6.81 (s, 1H), 3.29 (s, 3H), 2.33 (s, 3H), 1.40 (s, 18H); 13C NMR
(125 MHz, DMSO-d6) δ 159.47, 150.58, 148.91, 145.23, 143.57,
140.52, 140.14, 139.24, 131.68, 129.97, 129.12, 128.62, 126.55,
126.44, 117.93, 109.06, 43.83, 35.24, 30.87, 21.30; LRMS (EI)
m/z 559 (Mþ); HRMS (EI) m/z Calcd. C32H37N3O4S (M
þ)
559.2505, Found 559.2493.4.1.17. N-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-(4-methylsulfony-
lphenyl)-5-p-methoxyphenyl-1H-pyrazole-3-carboxamide (5c)
This compound was prepared from 40-methoxyacetophenone by
using a procedure similar to that described for the preparation of
4a. A yellow solid, mp 187–189 oC; 1H NMR (500 MHz,
DMSO-d6) δ 9.90 (s, 1H), 8.02 (d, J¼8.6 Hz, 2H), 7.67 (d,
J¼8.6 Hz, 2H), 7.64 (s, 2H), 7.27 (d, J¼8.7 Hz, 2H), 7.07 (s,
1H), 6.99 (d, J¼8.7 Hz, 2H), 6.81 (s, 1H), 3.78 (s, 3H), 3.28 (s,
3H), 1.40 (s, 18H); 13C NMR (125 MHz, DMSO-d6) δ 160.24,
159.55, 150.57, 148.77, 145.09, 143.63, 140.43, 140.14, 131.60,
130.67, 128.62, 126.41, 121.60, 117.93, 114.85, 108.81, 55.73,
43.84, 35.24, 30.87; LRMS (EI) m/z 575 (Mþ); HRMS (EI) m/z
Calcd. C32H37N3O5S (M
þ) 575.2454, Found 575.2447.4.1.18. N-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-(4-methylsulfonyl-
phenyl)-5-p-iso-butylphenyl-1H-pyrazole-3-carboxamide (5d)
This compound was prepared from 40-isobutylacetophenone by
using a procedure similar to that described for the preparation of
4a. A yellow solid, mp 238–240 oC; 1H NMR (500 MHz,
DMSO-d6) δ 9.91 (s, 1H), 8.01 (d, J¼8.6 Hz, 2H), 7.66 (d,
J¼8.6 Hz, 2H), 7.64 (s, 2H), 7.24 (q, J¼8.2 Hz, 4H), 7.12 (s,
1H), 6.81 (s, 1H), 3.28 (s, 3H), 2.48 (d, J¼7.2 Hz, 2H), 1.92–1.80
(m, 1H), 1.40 (s, 18H), 0.87 (s, 3H), 0.86 (s, 3H); 13C NMR
(125 MHz, DMSO-d6) δ 159.47, 150.58, 148.87, 145.32, 143.59,
142.79, 140.49, 140.14, 131.59, 129.93, 129.01, 128.57, 126.85,
126.38, 117.92, 109.09, 44.75, 43.83, 35.24, 30.87, 29.93, 22.62;
LRMS (EI) m/z 601 (Mþ); HRMS (EI) m/z Calcd. C35H43N3O4S
(Mþ) 601.2974, Found 601.2965.4.1.19. N-(3,5-di-tert-butyl-4-hydroxyphenyl)-5-(benzo [1, 3]
dioxol-5-yl)-1-(4-methylsulfonylphenyl)-1H-pyrazole-3-carboxamide
(5e)
This compound was prepared from 3,4-methylenedioxyacetophe-
none by using a procedure similar to that described for the
preparation of 1a. A pale yellow solid, mp 181–183 oC; 1H
NMR (500 MHz, DMSO-d6) δ 9.90 (s, 1H), 8.03 (d, J¼8.7 Hz,
2H), 7.69 (d, J¼8.7 Hz, 2H), 7.63 (s, 2H), 7.07 (s, 1H), 6.99–6.92
(m, 2H), 6.81 (s, 1 H), 6.79 (dd, J¼8.0, 1.7 Hz, 1H), 6.08 (s, 2H),
3.29 (s, 3H), 1.40 (s, 18H); 13C NMR (125 MHz, DMSO-d6) δ
159.50, 150.57, 148.70, 148.47, 148.04, 144.94, 143.51, 140.44,
140.14, 131.58, 128.59, 126.37, 123.59, 123.03, 117.94, 109.59,
109.19, 109.16, 102.07, 43.82, 35.24, 30.86; LRMS (EI) m/z 589
(Mþ); HRMS (EI) m/z Calcd. C32H35N3O6S (M
þ) 589.2247,
Found 589.2235.4.1.20. N-(3,5-di-tert-butyl-4-hydroxyphenyl)-5-(2,3-dihydrobenzo
[1, 4] dioxin-7-yl)-1-(4-methylsulfonylphenyl)-1H-pyrazole-3-
carboxamide (5f)
This compound was prepared from 1,4-benzodioxan-6-yl methyl
ketone by using a procedure similar to that described for the
preparation of 4a. A yellow solid, mp 153–156 oC; 1H NMR
(500 MHz, DMSO-d6) δ 9.89 (s, 1H), 8.03 (d, J¼8.6 Hz, 2H),
7.69 (d, J¼8.6 Hz, 2H), 7.63 (s, 2H), 7.06 (s, 1H), 6.91 (d,
J¼2.1 Hz, 1H), 6.89 (d, J¼8.4 Hz, 1H), 6.81 (s, 1H), 6.72 (dd,
J¼8.3, 2.1 Hz, 1H), 4.27 (dd, J¼10.1, 5.0 Hz, 4H), 3.29 (s, 3H),
1.39 (s, 18H); 13C NMR (125 MHz, DMSO-d6) δ 159.52, 150.57,
148.72, 144.77, 144.66, 143.92, 143.60, 140.48, 140.14, 131.59,
128.60, 126.44, 122.37, 118.02, 117.93, 108.98, 64.66, 64.52,
43.84, 35.24, 30.86; LRMS (EI) m/z 603 (Mþ); HRMS (EI) m/z
Calcd. C33H37N3O6S (M
þ) 603.2403, Found 603.2411.4.1.21. N-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-(4-methylsulfonyl-
phenyl)-5-naphth-2-yl-1H-pyrazole-3-carboxamide (5g)
This compound was prepared from 20-acetonaphthone by using a
procedure similar to that described for the preparation of 4a. A
white solid, mp 241–243 oC; 1H NMR (500 MHz, DMSO-d6) δ
9.98 (s, 1H), 8.06 (s, 1H), 8.01 (d, J¼8.6 Hz, 2H), 7.98–7.89 (m,
3H), 7.72 (d, J¼8.6 Hz, 2H), 7.67 (s, 2 H), 7.62–7.55 (m, 2H),
7.34 (dd, J¼8.5, 1.3 Hz, 1H), 7.28 (s, 1H), 6.84 (s, 1H), 3.28 (s,
3H), 1.42 (s, 18H); 13C NMR (125 MHz, DMSO-d6) δ 159.48,
150.61, 148.96, 145.15, 143.52, 140.53, 140.17, 133.14, 131.60,
128.88, 128.77, 128.74, 128.68, 128.18, 127.71, 127.42, 126.87,
126.43, 126.36, 117.96, 109.74, 43.83, 35.25, 30.88; LRMS (EI)
m/z 595 (Mþ); HRMS (EI) m/z Calcd. C35H37N3O4S (M
þ)
595.2505, Found 595.2500.4.1.22. N-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-(4-methylsulfony-
lphenyl)-5-p-tri-ﬂuoromethylphenyl-1H-pyrazole-3-carboxamide (5i)
This compound was prepared from 20-triﬂuoronaphthone by using
a procedure similar to that described for the preparation of 4a. A
pale yellow solid, mp 146–149 oC; 1H NMR (500 MHz,
DMSO-d6) δ 9.97 (s, 1H), 8.05 (d, J¼8.4 Hz, 2H), 7.81 (d,
J¼8.3 Hz, 2H), 7.71 (d, J¼8.4 Hz, 2H), 7.64 (s, 2H), 7.58 (d,
J¼8.1 Hz, 2H), 7.29 (s, 1H), 6.83 (s, 1H), 3.29 (s, 3H), 1.40 (s,
18H); 13C NMR (125 MHz, DMSO-d6) δ 159.30, 150.63, 149.01,
143.64, 143.18, 140.85, 140.15, 133.46, 131.54, 130.07, 128.80,
126.65, 126.29, 126.27, 117.97, 110.23, 43.83, 35.24, 30.86;
LRMS (EI) m/z 613 (Mþ); HRMS (EI) m/z Calcd.
C32H34F3N3O4S (M
þ) 613.2222, Found 613.2221.4.1.23. N-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-(4-methylsulfonyl-
phenyl)-5-cyclo-hexyl-1H-pyrazole-3-carboxamide (5j)
This compound was prepared from cyclohexyl methyl ketone by
using a procedure similar to that described for the preparation of
4a. A white solid, mp 183–185 oC; 1H NMR (500 MHz,
DMSO-d6) δ 9.76 (s, 1H), 8.14 (d, J¼8.6 Hz, 2H), 7.90 (d,
J¼8.5 Hz, 2H), 7.59 (s, 2H), 6.83 (s, 1H), 6.78 (s, 1H), 3.33 (s,
3H), 2.78 (t, J¼11.6 Hz, 1H), 1.89–1.59 (m, 5H), 1.48–1.16 (m,
23H); 13C NMR (125 MHz, DMSO-d6) δ 159.80, 151.67, 150.48,
148.40, 143.47, 141.00, 140.09, 131.58, 128.92, 126.83, 117.93,
105.34, 43.88, 35.22, 35.03, 33.13, 30.86, 26.09, 25.69; LRMS
(EI) m/z 551 (Mþ); HRMS (EI) m/z Calcd. C31H41N3O4S (M
þ)
551.2818, Found 551.2820.
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enyl)-5-phenyl-1H-pyrazole-3-carboxamide (6a)
This compound was prepared from acetophenone by using a
procedure similar to that described for the preparation of 4a. A
white solid, mp 232–234 oC; 1H NMR (500 MHz, DMSO-d6) δ
9.88 (s, 1H), 7.64 (s, 2H), 7.49–7.43 (m, 2H), 7.42–7.37 (m, 3H),
7.35–7.28 (m, 4H), 7.11 (s, 1H), 6.80 (s, 1H), 1.40 (s, 18H); 13C
NMR (125 MHz, DMSO-d6) δ 161.98 (d, J¼254.5 Hz), 159.68,
150.50, 148.05, 145.03, 140.09, 136.24, 131.67, 129.60, 129.29,
129.19, 129.11, 128.60 (d, J¼8.9 Hz), 117.96, 116.56 (d, J¼23.1
Hz), 108.30, 35.24, 30.87; LRMS (EI) m/z 485 (Mþ); HRMS (EI)
m/z Calcd. C30H32FN3O2 (M
þ) 485.2479, Found 485.2473.4.1.25. N-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-(4-ﬂuorophenyl)-
5-p-tolyl-1H-pyrazole-3-carboxamide (6b)
This compound was prepared from 40-methylacetophenone by
using a procedure similar to that described for the preparation of
4a. A white solid, mp 225–227 oC; 1H NMR (500 MHz, CDCl3) δ
8.63 (s, 1H), 7.56 (s, 2H), 7.40–7.33 (m, 2H), 7.18–7.09 (m, 7H),
5.11 (s, 1H), 2.38 (s, 3H), 1.49 (s, 18H); 13C NMR (125 MHz,
CDCl3) δ 162.09 (d, J¼249.1 Hz), 159.42, 150.56, 147.61,
145.54, 138.96, 136.51, 135.82, 129.87, 129.43, 128.66, 127.41
(d, J¼8.6 Hz), 126.52, 117.49, 116.14 (d, J¼23.0 Hz), 107.97,
34.54, 30.26, 21.30; LRMS (EI) m/z 499 (Mþ); HRMS (EI) m/z
Calcd. C31H34FN3O2 (M
þ) 499.2635, Found 499.2633.4.2. Biological evaluation
4.2.1. In vitro inhibition assays for 5-LOX product synthesis in
PMNL model
All derivatives (4a–k, 5a–j, and 6a–b, Table 1) were evaluated by
the cell-based assay for their inhibitory activities against 5-LOX
product synthesis in rat peritoneal leukocytes2,3 using zileuton as
the control drug. Mixed peritoneal leukocytes, including PMNLs
and mononuclear leukocytes, were obtained from SD rats receiv-
ing IP injection of 20 mL of 0.2% glycogen solution (10K154,
Sigma-Aldrich Co.). Brieﬂy, PMNLs were harvested with perito-
neal lavage using 10 mL of Hanks balanced salt solution (HBSS).
The resulting ﬂuid was centrifuged at 2000 r/min for 10 min. The
cells were resuspended with 5 mL of ice-cold distilled water to
disrupt blood red cells. After 1 min, 5 mL of 1.8% saline was
added. After centrifugation at 2000 r/min for 5 min, the cells were
washed twice with HBSS. PMNLs) were counted by wright-
Giemsa stain (PMNLs480%). The cell densities were adjusted
using HBSS to the concentration of 5 106 cells/mL. Aliquots
(0.5 mL) of the cell suspensions were preincubated at 37 1C for
10 min, followed by the addition of L-cysteine (10 mmol/L),
indomethacin (1 mg/L), and tested compounds or vehicle (0.1%
DMSO) in 96-well plates (Costar). Indomethacin was added to
prevent ex vivo formation of eicosanoids, which have the potential
to interfere with the assay. After 30 min, the cells were further
incubated with the calcium ionophore A23187 (5 μmol/L) at 37 1C
for 30 min. The mixtures were centrifuged at 14,000 r/min at 4 1C
for 5 min and the supernatants were collected and stored at 
70 oC until analysis. The amounts of LTB4 in the medium was
determined spectrophotometrically at 412 nm using commercial
enzyme immunoassay kits (Cayman Chemical Company, Ann
Arbor, USA).4.2.2. In vitro inhibition assays for 5-LOX product synthesis in
HWB model
Nine compounds were also evaluated for their inhibitory potency
against 5-LOX product synthesis in HWB challenged with
Ca2þ-ionophore A23187, using zileuton as the reference drug.
Fresh blood from a healthy volunteer was collected into test tubes
with heparin. Tested compounds were added to aliquots (0.5 mL)
of the whole blood and incubated for 15 min at 37 1C. After
addition of the Ca2þ ionophore A23187, the blood was incubated
at 37 1C for another 15 min. The mixtures were centrifuged at
12,000 r/min at 4 1C for 15 min and 400 μL of methanol was
added to the supernatant fractions. After further vortexing and
incubation, the supernatants were collected and stored at 70 oC
until analysis. The amounts of LTB4 in the medium was
determined spectrophotometrically at 412 nm using commercial
enzyme immunoassay kits (Lot No. 143772, Cayman Chemical
Company, Ann Arbor, USA).4.2.3. Evaluation of 5-LOX inhibitory activity in a cell-free
assay
The enzyme assay is based on the oxidation of the substrate H2DCFDA
to the highly ﬂuorescent product 20,70-dichloro-ﬂuorescein (DCF)28.
Nonspeciﬁc ester cleavage of the acetate groups of H2DCFDA was
carried out prior to the oxidation by incubation of 20 μmol/L
H2DCFDA with 3.34 mU/μL 5-LOX in the assay buffer (50 mmol/L
Tris, 2 mmol/L CaCl2, pH 7.5) (Reagent A). Speciﬁcally, 40 μL of
reagent A was added into the well of a 96-well plate (Costar Catalog
No. 3915). The plate was shaken for 1 min and allowed to stand for
5 min. 1 μL of various concentrations of inhibitors were then added to
the wells. After incubation for 10 min, the reaction was initiated by the
addition of 40 μL of Reagent B (10 μmol/L AA, 20 μmol/L ATP) with
shaking for 1 min. The reaction was stopped by the addition of 80 μL
pure acetonitrile after 20 min. The ﬂuorescence at 520 nm was
measured with the excitation light of 485 nm on POLARstar OPTIMA
microplate reader (BMG LabTech, Offenburg, Germany). Zileuton was
used as the positive control.4.2.4. Quantiﬁcation of LPS-induced generation of the proinﬂa-
mmatory mediator nitric oxide in microglial BV2 cells
To assess the suppressive effects of compound 4e on LPS-
induced inﬂammation in brain-resident inﬂammatory cells, we
used a mouse microglia cell line BV2. BV2 cells were cultured
in Dulbecco's modiﬁed Eagle's Medium (DMEM, Invitrogen
Corporation, Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum (FBS, Gibco Laboratories, Grand Island, NY,
USA) and 100 μg/mL penicillin-streptomycin at 37 1C with 5%
CO2. Cells were trypsinized, seeded onto 96-well plates at the
density of 2 104 cells per well per 100 μL and exposed to
compound 4e in the presence or absence of LPS (200 ng/mL) at
24 h after seeding. Cell Supernatants were harvested at 24 h
after exposure for the measurement of the stable end product of
NO, nitrite (NO), using Griess reagents as described pre-
viously29. Brieﬂy, supernatants (50 μL) were mixed with 50 μL
Griess reagent, which reacted with nitrite to form a compound
spectrophotometrically detectable at 570 nm. Furthermore, the
effects of compound 4e on cell viability was assessed with 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT)30. Brieﬂy, cells were incubated in medium containing
of MTT (0.5 mg/mL) at 37 1C with 5% CO2 for 2 h. Then,
medium was aspirated and cells were lysed with 100 mL DMSO
to dissolve dark blue crystals of formazan, a MTT metabolite
Yu Zhou et al.44formed only in live cells but not in dead cells. The absorbance
was measured at 570 nm using the Microplate Reader (Inﬁnite
M200 PRO, Tecan, Switzerland). Relative cell viabilities were
calculated and presented as percentages of controls without
glutamate treatment.4.2.5. Assessment of neuroprotective effects of 4e against gluta-
mate-induced oxidative toxicity in the hippocampal neuronal cell line
HT22
We assessed the neuroprotective effects of the compound 4e
against glutamate-induced oxidative toxicity in HT22 cells, as
previously described31. Brieﬂy, mouse hippocampal HT22 cells
were cultured in Dulbecco's modiﬁed Eagle's Medium (DMEM,
Invitrogen Corporation, Carlsbad, CA, USA) supplemented with
10% fetal bovine serum (FBS, Gibco Laboratories, Grand Island,
NY, USA) and 100 μg/mL penicillin-streptomycin at 37 1C with
5% CO2. The medium was changed every two days. For the
glutamate toxicity assay, cells were trypsinized and seeded onto
24-well plates at the density of 2 104 cells per well. After a 24 h
incubation the cells were exposed to glutamate at ﬁnal concentra-
tion of 5 mmol/L in the presence or absence of compound 4e. At
24 h after glutamate addition cell viabilities were measured with
MTT4 as described in earlier. Relative cell viabilities were
calculated and presented as a percentage of control without
glutamate treatment.4.2.6. Assessment of protective effects of 4e against ischemic
damage in a mouse middle cerebral artery occlusion model
Animal experiments were approved by the Ethical Review Panel
of Soochow University. Adult male CD-1 mice weighing 3072 g
were used in the study. Experimental stroke was induced in mice
by middle cerebral artery occlusion (MCAO) via the intraluminal
suture technique, as described32. Brieﬂy, mice were anesthetized
with isoﬂurane and body temperature was maintained by warming
pads during surgery33. A skin incision was made to expose the
right external and common carotid arteries. After the common
carotid artery was tightened, a silicon-coated nylon suture with a
heat-blunted tip (diameter 0.2270.02 mm) was inserted into the
right internal carotid artery via the external carotid artery. The
suture was secured and the surgical site was closed when the tip of
the suture reached the origin of the middle cerebral artery. After
60 min of occlusion, the suture was withdrawn to allow for
reperfusion. Vascular occlusion (o25% of baseline) and reperfu-
sion (475% of baseline) were veriﬁed with laser Doppler
ﬂowmetry (PeriFlux System 5000, Perimed Inc, Stockholm,
Sweden) by afﬁxing a laser probe to the mouse skull to monitor
cortical perfusion. At 3 h after reperfusion, mice showing obvious
neurological deﬁcits were randomly divided into two groups to
receive: 1) intraperitoneal (IP) injection of the compound 4e at a
dose of 50 mg/kg; or 2) an equal volume of vehicle (10 μL DMSO
suspended in 490 μL corn oil). At 24 h after MCAO, mice were
decapitated. Brains were harvested and cut into 2-mm-thick
coronal sections. Slices were stained in a 1.2% solution of 2,3,5-
triphenyltetrazolium chloride (TTC, Sigma, St Louis, MO, USA)
and then photographed. Unstained (infarcted) and stained (unin-
farcted) areas were analyzed with digital image analysis software
(SigmaScan Pro, Jandel, San Rafael, CA, USA) and integrated
across all slices, as previously described33.4.3. Molecular modeling
4.3.1. Preparing the protein structure
The X-ray crystal structure of arachidonic acid bound to 5-LOX
was retrieved from the Protein Data Bank (PDB ID: 3V99). The
solvent molecules were deleted, and the remaining protein
structure was prepared using the Protein Preparation Wizard
module in the Maestro program (version 9.1. Schrödinger, LLC,
New York, NY; 2010). In brief, the hydrogen atoms were properly
added to the complexes, bond corrections were applied to the
cocrystallized ligand, the hydrogen bond networks and ﬂip
orientations/tautomeric states of Gln, Asn, and His residues were
optimized to maximize hydrogen bond formation, and an exhaus-
tive sampling was performed with regard to hydrogen bond
assignment. Finally, a restrained minimization on the ligand–
protein complexes was performed with the OPLS_2005 force ﬁeld
and the default value for rmsd of 0.30 Å for non-hydrogen atoms
was used.4.3.2. Ligand preparation
The three-dimensional (3D) coordinates of the synthesized com-
pounds were generated with LigPrep (version 2.4. Schrödinger,
LLC, New York, NY; 2010), and their protonation states were
determined at a target pH 7.072.0 with Epik (version 2.1. Schro–
dinger, LLC, New York, NY; 2010). The resulting structures were
used as the starting point for the followed docking simulations.4.3.3. Induced ﬁt docking
The Glide (version 5.6. Schrödinger, LLC, New York, NY; 2010)
grid was deﬁned as an enclosing box centered at the native ligand
arachidonic acid, with the box size 18 Å 18 Å 18 Å. The IFD
protocol was carried out in three consecutive steps. Firstly, the
ligand was docked into a ﬂexible receptor model, with manually
chosen rotatable residues: Tyr181, Phe177, Thr427. Next, the
Prime (version 2.2. Schrödinger, LLC, New York, NY; 2010.)
program was used to generate the induced-ﬁt protein–ligand
complex with default parameters. Finally, the extra precision
(XP) Glide docking method was used to dock the compound of
interest ﬂexibly into the arachidonic acid binding site of 5-LOX.
To verify the docking protocol, a redocking validation was ﬁrstly
performed and the top-scored (Gscore) binding pose of the native
ligand (arachidonic acid) is close to its crystal structure conforma-
tion, with a small RMSD value of 1.2 Å. Accordingly, the IFD
protocol was used for the followed binding mode analysis of our
active compounds.Acknowledgments
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